Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco M Muggia

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell linesYi-He Ling, Leonard Liebes, Jian-Dong Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancerDeepu Mirchandani, Howard Hochster, Anne Hamilton, et al.
Cancer|February 6, 2009
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group studyChunqiao Tian, Maurie Markman, Richard Zaino, et al.
Anti-Cancer Drugs|October 24, 2002
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 daysFranco M Muggia, Leonard Liebes, Maitreyee Hazarika, et al.
Molecular Cancer Therapeutics|December 21, 2002
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosisYi-He Ling, Leonard Liebes, Bruce Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Gynecologic Oncology|September 15, 2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessmentStephanie V Blank, Paul Christos, John P Curtin, et al.
Anti-Cancer Drugs|April 8, 2003
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignanciesMissak Haigentz, Mimi Kim, Joan Sorich, et al.
Plos One|January 26, 2010
A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanomaPatrick A Ott, Anne Hamilton, Amanda Jones, et al.
Cancer|January 22, 2009
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group studyKristin K Zorn, Chunqiao Tian, William P McGuire, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell linesYi-He Ling, Leonard Liebes, Jian-Dong Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancerDeepu Mirchandani, Howard Hochster, Anne Hamilton, et al.
Cancer|February 6, 2009
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group studyChunqiao Tian, Maurie Markman, Richard Zaino, et al.
Anti-Cancer Drugs|October 24, 2002
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 daysFranco M Muggia, Leonard Liebes, Maitreyee Hazarika, et al.
Molecular Cancer Therapeutics|December 21, 2002
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosisYi-He Ling, Leonard Liebes, Bruce Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Gynecologic Oncology|September 15, 2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessmentStephanie V Blank, Paul Christos, John P Curtin, et al.
Anti-Cancer Drugs|April 8, 2003
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignanciesMissak Haigentz, Mimi Kim, Joan Sorich, et al.
Plos One|January 26, 2010
A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanomaPatrick A Ott, Anne Hamilton, Amanda Jones, et al.
Cancer|January 22, 2009
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group studyKristin K Zorn, Chunqiao Tian, William P McGuire, et al.
Pageof 6